Two-stage approach to primary TKA in infected arthritic knees using intraoperatively molded articulating cement spacers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shaikh, A.A. | - |
dc.contributor.author | Ha, C.W. | - |
dc.contributor.author | Park, Y.G. | - |
dc.contributor.author | Park, Yong Beom | - |
dc.date.available | 2020-08-24T07:20:35Z | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 0009-921X | - |
dc.identifier.issn | 1528-1132 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/43297 | - |
dc.description.abstract | Background: The treatment of knee arthritis with coexistent bone or joint sepsis is challenging. Despite the condition causing considerable morbidity, there is no generally agreed-upon approach to its treatment. Description of Technique: We used aggressive débridement of the knee and implantation of intraoperatively molded articulating antibiotic cement spacers with 4 g vancomycin and 2 g streptomycin per bag of cement for patients with unknown organisms as a first stage. When the infecting organism was known, organism-specific antibiotics were used. For fungal infections, 400 mg amphotericin B was added per bag of cement. This was followed by TKA as a second stage once soft tissues had healed 2 to 29 months later, (mean, 6 months) and return of laboratory parameters to within a normal range. One patient underwent two débridement and spacer procedures for suspected persistent infection. Methods: To determine whether this approach resulted in adequate control of infection and satisfactory scores for pain and function, we retrospectively reviewed 15 patients who presented with infected arthritic knees between 2001 and 2009; all patients with infected arthritic knees were treated with this same technique during this period. We assessed knee ROM, Knee Society scores, WOMAC scores, and VAS scores preoperatively and during followup. Followup was at a mean of 4 years (range, 2-7 years); No patient was lost to followup before 2 years. Results: Two of the 15 patients were comfortable with the spacers and declined a more definitive reconstruction, and no patient had a recurrent infection after TKA. Before spacer placement, the mean ROM was 103.° (range, 60°-150°), with the spacers in place it decreased to a mean 87° (range, 60°-135°), and after TKA it improved to a mean of 115° (range, 75°-150°). The mean Knee Society Knee and Function scores progressed from 41 and 43 preoperatively to 85 and 83 at latest followup, respectively. The WOMAC scores improved from 51 initially to 18 after TKA. The mean VAS scores improved from 66 preoperatively to 18 after the TKA. Conclusions: In this small proof-of-concept series, we found that joint débridement and use of intraoperatively molded articulating antibiotic cement spacers as part of a staged approach to treat the infected arthritic knee before TKA resulted in infection control in all patients at a minimum of 2 years' followup, reduction of knee pain, and restoration of knee function. We suggest that larger, comparative series be performed to further validate these results. © 2014 The Association of Bone and Joint Surgeons®. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Springer New York LLC | - |
dc.title | Two-stage approach to primary TKA in infected arthritic knees using intraoperatively molded articulating cement spacers | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s11999-014-3545-6 | - |
dc.identifier.bibliographicCitation | Clinical Orthopaedics and Related Research, v.472, no.7, pp 2201 - 2207 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000337021300032 | - |
dc.identifier.scopusid | 2-s2.0-84904107561 | - |
dc.citation.endPage | 2207 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 2201 | - |
dc.citation.title | Clinical Orthopaedics and Related Research | - |
dc.citation.volume | 472 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | amphotericin B | - |
dc.subject.keywordPlus | antibiotic agent | - |
dc.subject.keywordPlus | C reactive protein | - |
dc.subject.keywordPlus | palacos | - |
dc.subject.keywordPlus | streptomycin | - |
dc.subject.keywordPlus | vancomycin | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | analgesia | - |
dc.subject.keywordPlus | anterior cruciate ligament reconstruction | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | asthma | - |
dc.subject.keywordPlus | bacterial arthritis | - |
dc.subject.keywordPlus | cement spacer | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | debridement | - |
dc.subject.keywordPlus | erythrocyte sedimentation rate | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypopituitarism | - |
dc.subject.keywordPlus | infection | - |
dc.subject.keywordPlus | infection control | - |
dc.subject.keywordPlus | knee arthritis | - |
dc.subject.keywordPlus | knee function | - |
dc.subject.keywordPlus | knee pain | - |
dc.subject.keywordPlus | Knee Society Score | - |
dc.subject.keywordPlus | leukocyte differential count | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multiple trauma | - |
dc.subject.keywordPlus | mycosis | - |
dc.subject.keywordPlus | osteomyelitis | - |
dc.subject.keywordPlus | passive movement | - |
dc.subject.keywordPlus | peroperative care | - |
dc.subject.keywordPlus | persistent infection | - |
dc.subject.keywordPlus | physiotherapy | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | recurrent infection | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | spine surgery | - |
dc.subject.keywordPlus | surgical approach | - |
dc.subject.keywordPlus | total knee replacement | - |
dc.subject.keywordPlus | tuberculosis | - |
dc.subject.keywordPlus | visual analog scale | - |
dc.subject.keywordPlus | Western Ontario and McMaster Universities Osteoarthritis Index | - |
dc.subject.keywordPlus | Bone Diseases, Infectious | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Aged, 80 and over | - |
dc.subject.keywordPlus | Anti-Bacterial Agents | - |
dc.subject.keywordPlus | Arthroplasty, Replacement, Knee | - |
dc.subject.keywordPlus | Biomechanical Phenomena | - |
dc.subject.keywordPlus | Bone Cements | - |
dc.subject.keywordPlus | Debridement | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Infection Control | - |
dc.subject.keywordPlus | Knee Joint | - |
dc.subject.keywordPlus | Knee Prosthesis | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Osteoarthritis, Knee | - |
dc.subject.keywordPlus | Prosthesis Design | - |
dc.subject.keywordPlus | Prosthesis-Related Infections | - |
dc.subject.keywordPlus | Range of Motion, Articular | - |
dc.subject.keywordPlus | Recovery of Function | - |
dc.subject.keywordPlus | Sepsis | - |
dc.subject.keywordPlus | Streptomycin | - |
dc.subject.keywordPlus | Time Factors | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordPlus | Vancomycin | - |
dc.relation.journalResearchArea | Orthopedics | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Orthopedics | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.